Identification of Novel Human Immunodeficiency Virus-1 Integrase Inhibitors by Shape-Based Virtual Screening
T.K. Omprakash1, A. Thamarai Selvan1, A. Shahul Hameed1 & S.P. Geetha1 Show affiliations
- Thiagarajar College, Madurai-625009, India
Current Research in Medicine, Volume 1, Issue 2, pp. 151–156 · doi.org/10.3844/amjsp.2010.151.156
Abstract
Problem statement: Human Immunodeficiency Virus-1 (HIV-1) is causative agent of the immune system disease, Acquired Immune Deficiency Syndrome (AIDS). Majority of anti-HIV drugs target reverse transcriptase and protease enzymes. Toxicity and development of multidrug resistant HIV-1 virus strains are the reasons for studying new targets in HIV-1 replication process for identifying novel inhibitor with low toxicity and high activity. Approach: In this study, ROCS software was used to identify the novel HIV-1 Integrase (HIV-1 IN) inhibitor by shape-based virtual screening. The currently used drug raltegravir was used as query molecule. Results: Here five novel molecules were identified, among them Rank 5 molecule was shown to have higher structural and electrostatic similarity to query molecule and this molecule was considered as good inhibitor of HIV-1 IN enzyme. Conclusion: ROCS, EON and FRED effectively identified one active inhibitor of HIV-1 IN among five compounds, which was similar to the query molecule and this study showed that ROCS, EON and FRED can play a vital role in drug discovery projects.
Licence and reuse
Free to read. This article carries the publisher’s copyright, as printed on it: © 2010 Science Publications. It is free to read; ask us before reusing it.
How to reuse this articleResponses (0)
About this article
Omprakash, T., Selvan, A. T., Hameed, A. S. & Geetha, S. (2010). Identification of Novel Human Immunodeficiency Virus-1 Integrase Inhibitors by Shape-Based Virtual Screening. Current Research in Medicine, 1(2), 151–156. https://doi.org/10.3844/amjsp.2010.151.156
- Licence
- © Science Publications
- Issue
- Volume 1, Issue 2
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record
